Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 113

1.

Cost-effectiveness of new pneumococcal conjugate vaccines in Turkey: a decision analytical model.

Bakır M, Türel O, Topachevskyi O.

BMC Health Serv Res. 2012 Nov 9;12:386. doi: 10.1186/1472-6963-12-386.

2.

Cost-effectiveness and cost utility analysis of three pneumococcal conjugate vaccines in children of Peru.

Gomez JA, Tirado JC, Navarro Rojas AA, Castrejon Alba MM, Topachevskyi O.

BMC Public Health. 2013 Oct 30;13:1025. doi: 10.1186/1471-2458-13-1025.

3.

Cost-effectiveness of conjugate pneumococcal vaccination in Singapore: comparing estimates for 7-valent, 10-valent, and 13-valent vaccines.

Tyo KR, Rosen MM, Zeng W, Yap M, Pwee KH, Ang LW, Shepard DS.

Vaccine. 2011 Sep 2;29(38):6686-94. doi: 10.1016/j.vaccine.2011.06.091. Epub 2011 Jul 13.

PMID:
21745516
4.

Modeling the impact of a new vaccine on pneumococcal and nontypable Haemophilus influenzae diseases: a new simulation model.

De Wals P, Black S, Borrow R, Pearce D.

Clin Ther. 2009 Oct;31(10):2152-69. doi: 10.1016/j.clinthera.2009.10.014.

PMID:
19922887
5.

Economic evaluation of childhood 7-valent pneumococcal conjugate vaccination in Korea.

Sohn HS, Suh DC, Jang E, Kwon JW.

J Manag Care Pharm. 2010 Jan-Feb;16(1):32-45.

6.

Outcomes and costs associated with PHiD-CV, a new protein D conjugate pneumococcal vaccine, in four countries.

Talbird SE, Taylor TN, Knoll S, Frostad CR, García Martí S.

Vaccine. 2010 Nov 19;28 Suppl 6:G23-9. doi: 10.1016/j.vaccine.2010.06.016.

PMID:
21075266
7.

Cost effectiveness of pneumococcal vaccination among Dutch infants: economic analysis of the seven valent pneumococcal conjugated vaccine and forecast for the 10 valent and 13 valent vaccines.

Rozenbaum MH, Sanders EA, van Hoek AJ, Jansen AG, van der Ende A, van den Dobbelsteen G, Rodenburg GD, Hak E, Postma MJ.

BMJ. 2010 Jun 2;340:c2509. doi: 10.1136/bmj.c2509.

8.
9.

Comparing health outcomes and costs of general vaccination with pneumococcal conjugate vaccines in Sweden: a Markov model.

By A, Sobocki P, Forsgren A, Silfverdal SA.

Clin Ther. 2012 Jan;34(1):177-89. doi: 10.1016/j.clinthera.2011.12.007.

PMID:
22284997
10.

Cost-Effectiveness Evaluation of the 10-Valent Pneumococcal Non-typeable Haemophilus influenzae Protein D Conjugate Vaccine and 13-Valent Pneumococcal Vaccine in Japanese Children.

Shiragami M, Mizukami A, Leeuwenkamp O, Mrkvan T, Delgleize E, Kurono Y, Iwata S.

Infect Dis Ther. 2014 Dec 20. [Epub ahead of print]

11.

Potential cost-effectiveness of pneumococcal conjugate vaccine (PCV) in Turkey.

Türel O, Kisa A, McIntosh ED, Bakir M.

Value Health. 2013 Jul-Aug;16(5):755-9. doi: 10.1016/j.jval.2013.03.1632. Epub 2013 Jul 10.

12.

A pharmacoeconomic evaluation of seven-valent pneumococcal conjugate vaccine in Spain.

Asensi F, De Jose M, Lorente M, Moraga F, Ciuryla V, Arikian S, Casciano R, Vento M.

Value Health. 2004 Jan-Feb;7(1):36-51.

13.

[Economic evaluation of an infant immunization program in Mexico, based on 13-valent pneumococcal conjugated vaccines].

Muciño-Ortega E, Mould-Quevedo JF, Farkouh R, Strutton D.

Value Health. 2011 Jul-Aug;14(5 Suppl 1):S65-70. doi: 10.1016/j.jval.2011.05.025. Spanish.

14.

Cost-effectiveness of pneumococcal conjugate vaccination in Croatia.

Vučina VV, Filipović SK, Kožnjak N, Stamenić V, Clark AD, Mounaud B, Blau J, Hoestlandt C, Kaić B.

Vaccine. 2015 May 7;33 Suppl 1:A209-18. doi: 10.1016/j.vaccine.2014.12.043.

PMID:
25919163
15.

Cost effectiveness of adding 7-valent pneumococcal conjugate (PCV-7) vaccine to the Norwegian childhood vaccination program.

Wisløff T, Abrahamsen TG, Bergsaker MA, Løvoll Ø, Møller P, Pedersen MK, Kristiansen IS.

Vaccine. 2006 Jul 17;24(29-30):5690-9. Epub 2006 May 5.

PMID:
16735083
17.

Cost-effectiveness analysis of routine pneumococcal vaccination in the UK: a comparison of the PHiD-CV vaccine and the PCV-13 vaccine using a Markov model.

Delgleize E, Leeuwenkamp O, Theodorou E, Van de Velde N.

BMJ Open. 2016 Nov 30;6(11):e010776. doi: 10.1136/bmjopen-2015-010776.

18.

Cost-effectiveness analysis of the 10- and 13-valent pneumococcal conjugate vaccines in Argentina.

Urueña A, Pippo T, Betelu MS, Virgilio F, Giglio N, Gentile A, Jimenez SG, Jáuregui B, Clark AD, Diosque M, Vizzotti C.

Vaccine. 2011 Jul 12;29(31):4963-72. doi: 10.1016/j.vaccine.2011.04.111. Epub 2011 May 27.

PMID:
21621575
19.

Economic evaluation of second generation pneumococcal conjugate vaccines in Norway.

Robberstad B, Frostad CR, Akselsen PE, Kværner KJ, Berstad AK.

Vaccine. 2011 Nov 3;29(47):8564-74. doi: 10.1016/j.vaccine.2011.09.025. Epub 2011 Sep 21.

PMID:
21945264
20.

Cost-effectiveness of 2 + 1 dosing of 13-valent and 10-valent pneumococcal conjugate vaccines in Canada.

Earnshaw SR, McDade CL, Zanotti G, Farkouh RA, Strutton D.

BMC Infect Dis. 2012 Apr 24;12:101. doi: 10.1186/1471-2334-12-101.

Supplemental Content

Support Center